The Foreign Service Benefit Plan (FSBP) will reinstate participation requirements for the EncircleRx program beginning March 1, 2026, following corrective action to address earlier implementation issues.

At the start of this year, FSBP launched the EncircleRx program in partnership with Evernorth/Express Scripts and Teladoc Health. This program requires members who are prescribed a GLP-1 medication for weight management and who have that prescription filled in the United States to enroll in either the Teladoc Advanced Weight Management Program or the Teladoc Advanced Pre-Diabetes Program. The program is designed to provide structured clinical support, digital tools, and coaching to help members manage their health effectively while using these medications.

During the initial rollout, some members experienced challenges, including difficulty locating the appropriate program within the Teladoc app, delays in prior authorization submissions, and communication issues between Teladoc and Express Scripts that affected enrollment confirmation. As a result, participation requirements were temporarily suspended while system improvements were implemented.

After several weeks of corrective work and performance monitoring, the identified issues have been resolved.

Participation requirements will resume effective March 1, 2026.

What This Means for Members

Members prescribed a GLP-1 medication for weight management must:

1. Enroll in either the Teladoc Advanced Weight Management Program or the Teladoc Advanced Pre-Diabetes Program prior to their first 2026 prescription fill.
2. For refills, complete at least four (4) weigh-ins per month using the Teladoc-provided scale and engage with the Teladoc app at least four (4) times per month (such as tracking meals or activity, reading educational content, or participating in coaching sessions).
3. Ensure their provider submits an updated prior authorization through EviCore (online) or by calling 800-417-1764. Documentation must include baseline BMI and any applicable comorbidities. Prior authorizations must be completed by the prescribing provider.

To ensure members are informed, an email was sent to affected members on February 24. A follow-up letter will also be mailed to affected members by the end of next week.

FSBP encourages members currently using or planning to use a GLP-1 medication for weight management to review the program requirements and confirm enrollment and prior authorization status to help prevent delays in medication access.